Catalyst Wire Dossier Catalyst Wire Dossier

Selective androgen receptor modulator (SARM) studied in trial NCT02499497

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Selective androgen receptor modulator (SARM) studied in trial NCT02499497, covering 2021-09-28 to 2021-09-28. Get the full timeline:

Most recent: Clinical Trial Update: A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer [Phase 2]

See pricing